ANNUAL REPORT

LIFEHOUSE GYNAECOLOGICAL

ONCOLOGY GROUP

2014

Prepared by

Professor Jonathan Carter

MBBS, DipRACOG, FACS, FRANZCOG, MS, MD, CGO Professor Gynaecological Oncology, The University of Sydney

Head, Lifehouse Gynaecological Oncology Group

2

3

Table of Contents

Introduction ......................................................................................................................... 4

Highlights .............................................................................................................................. 5

Summary Statistics ............................................................................................................. 6 2014 Quality Performance Indicator Numbers ................................................................ 6 Patient Activity 2008-2014 ...................................................................................................... 7 Surgical Load ................................................................................................................................. 8 Length of Stay ................................................................................................................................ 8 Quality Performance Indicator Incidence for Malignant Patients 2014 ...............10 Cumulative Quality Performance Indicator Incidence for Malignant Patients 2009-2014 ....................................................................................................................................11 Adverse Events 2014 ................................................................................................................12 Meeting Attendance ..................................................................................................................13

Publications ....................................................................................................................... 14

International Presentations ........................................................................................ 15

National Presentations .................................................................................................. 15

Local Presentations......................................................................................................... 17

Abstracts ............................................................................................................................. 17

Invited Lectureship, Guest or Program Chair ........................................................ 18

Grants and Awards (+/-Submitted) .......................................................................... 19

Research Supervision ..................................................................................................... 19

Ethics Approved Studies ............................................................................................... 20

Grant, Trial, Thesis & Manuscript Reviews ............................................................ 21

Appointments ................................................................................................................... 23

Administrative Responsibilities ................................................................................. 23

Course Organisation ....................................................................................................... 23

Committee Membership ................................................................................................ 24

Selection Committees ..................................................................................................... 24

Media & Fund Raising..................................................................................................... 25

College Activities; Lectures .......................................................................................... 25

University Activities ....................................................................................................... 25

Courses/Conferences Attended .................................................................................. 27

Trials List ............................................................................................................................ 29

4

Introduction It has been quite a momentous year, having completed our first year in The Chris O’Brien Lifehouse. We are delighted with the new premises, with our new approach to care and have received nothing but compliments from our patients. Our Group currently comprises 4 surgeons, Prof Jonathan Carter, Clin A/Prof Selvan Path, Clin A/Prof Sam Saidi and Clin A/Prof Trevor Tejada-Berges. Our senior nurses include Shannon Philp our Nurse Practitioner and Jayne Manalang our

Clinical Nurse Consultant. Our clinical Fellows are Dr Unine Herbst and Dr Tony Richards. Dr Stephen Cotterell is our Data Manager and Database programmer and Christine Young remains our ever faithful Patient Navigator. Our newest team member is Gel Bolanos our registered nurse in Clinical Trials. Our extended Multidisciplinary Team include Dr Lyndal Anderson (Pathology), Dr Wendy Brown, Dr Sam McCormack and Dr YuXuan Kitzing (Radiology), A/Prof Philip Beale and Dr Michelle Harrison (Medical Oncology), A/Prof Chris Milross, Clin Assoc Prof Kerwyn Foo, Dr Joanne Toohey (Radiation Oncology), Camron Ebzeny and Annabelle Ng (Genetics). Overall we continue to excel, not only in patient care, but in teaching, education, research and administration. We have been able to maintain and improve upon our standards and achievements from previous years, with the expectation that this will continue into 2015 and beyond. My plans for the future include the development of a tertiary ovarian cancer surgical unit and to assist Lifehouse in developing a robotic surgical program.

5

Highlights

Shannon Philp and A/Prof Tejada-Berges have initiated and developed Australia’s first, Nurse Practitioner Led GTD Clinic at Lifehouse

Dr Tejada-Berges received academic promotion to Clinical Associate Professor

Dr Unine Herbst joined our Group as Clinical Fellow

Dr Richards successfully passed the oral and written CGO examination

A/Prof Pather was elected to the Human Research Ethics Committee

Dr Anderson was invited for the National Representative for National Coalition of Public Pathology for “Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014

Dr Anderson and co-investigators including Prof Carter received Sydney Local Health District Cancer Services Research Grant for the study of Next Generation Sequencing of HPV driven cervical carcinomas.

Our Group successfully presented our 10th Annual Advances in Gynaecological Oncology Symposium

6

Summary Statistics Prof

Carter A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Inpatients Malignant 63 84 47 50

Benign 134 109 59 97

Consults 9 8 4 3

Total Inpatients 206 201 110 150

Outpatients 1538 2081 1260 1239

Total Inpatient/Outpatient 1744 2282 1370 1389

New cancers 43 72 38 54

2014 Quality Performance Indicator Numbers

Prof

Carter A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Admission to ICU 2 1

Anastomotic Leak

Bladder Injury 1 1

Bowel Injury 1 1 1 1

Death from Treatment Complications

Death within 30 days of surgery

DVT or PE 1

Febrile Morbidity 2 1 1

Hospital Readmission 6 3 5 2

Laparoscopy converted to laparotomy 1 1 1

LOS more than 7 days 2 7 2 9

Nerve Injury 1

Nosocomial Infection 1

Perioperative Cardiac Event

Perioperative Respiratory Event 1

Post-operative Renal Impairment 1 4

Return to OT 1 1 2

Transfusion Intra Op 1 3 2

Transfusion Post Op 1 3 1

Transfusion Pre Op

Treatment Refusal

Undiagnosed Cancer 1

Ureteric Injury

Vascular Injury

Wound Dehiscence 1 1

Superficial Diathermy Burn

Inadvertent Diathermy Bowel

7

Patient Activity 2008-2014

0

500

1000

1500

2000

2500

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Inpatien

ts

Opu

tpatien

ts

Ne

w C

an

ce

rs

Prof Carter A/Prof Pather Dr Dalrymple Dr Tang Dr Saidi Dr Tejada-Berges

Patient Activity 2008-2014

2008

2009

2010

2011

2012

2013

2014

8

Surgical Load

Surgical Load Prof Carter A/Prof

Pather A/Prof Saidi

A/Prof Tejada-Berges

Laparotomy 42 19 15 31

Laparoscopy 7 45 44 28

Vulva 8 12 1 3

Conversions 1 0 1 1

Surgical Other 2 11 3 10

Non Surgical 11 10 10 7

Length of Stay

LOS Prof Carter A/Prof

Pather A/Prof Saidi

A/Prof Tejada-Berges

Overall Average LOS 3.17 2.76 2.12 3.66

Overall Median LOS 2.5 2 2 2

Laparotomy 3 3 3 3

Laparoscopy 1 1 1 1

Vulva 2.5 2.5 1 1

Surgical Other 2 3 2 2.5

Non Surgical 3 2.5 2 4

Note: Figures apply to surgery on patients with malignancy who were admitted to the ward (TPU patients not included here).

9

0

1

2

3

4

5

6

Prof Carter Dr Dalrymple A/Prof Pather Dr Tang Dr Saidi Dr Tejada-Berges

Days

Average Length of Stay 2009-2014

2009 2010 2011

2012 2013 2014

10

Quality Performance Indicator Incidence for Malignant Patients 2014

Expressed as a percentage of malignant surgeries performed

Prof Carter

A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Admission to ICU 0.8% 0.4%

Anastomotic Leak Bladder Injury 0.4% 0.4% Bowel Injury 0.4% 0.4% 0.4% 0.4%

Death from Treatment Complications Death within 30 days of surgery DVT or PE 0.4%

Febrile Morbidity 0.8% 0.4% 0.4%

Hospital Readmission 2.5% 1.3% 2.1% 0.8%

Laparoscopy converted to laparotomy 0.4% 0.4% 0.4%

LOS more than 7 days 0.8% 2.9% 0.8% 3.8%

Nerve Injury 0.4% Nosocomial Infection 0.4% Perioperative Cardiac Event Perioperative Respiratory Event 0.4%

Post-operative Renal Impairment 0.4% 1.7%

Return to OT 0.4% 0.4% 0.8%

Transfusion Intra Op 0.4% 1.3% 0.8%

Transfusion Post Op 0.4% 1.3% 0.4%

Transfusion Pre Op Treatment Refusal

Undiagnosed Cancer

0.4% Ureteric Injury

Vascular Injury Wound Dehiscence

0.4% 0.4%

Superficial Diathermy Burn Inadvertent Diathermy Bowel

11

Cumulative Quality Performance Indicator Incidence for Malignant Patients 2009-2014

Prof Carter

Dr Dalrymple

A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Admission to ICU 9 1 5 1 1

Anastomotic Leak

Bladder Injury 2 2

Bowel Injury 4 4 1 1

Death from Treatment Complications

Death within 30 days of surgery 2

DVT or PE 7 1 1

Febrile Morbidity 2 1 1

Hospital Readmission 27 3 22 7 2

Laparoscopy converted to laparotomy 4 3 15 1 1

LOS more than 7 days 40 17 72 2 9

Nerve Injury 2

Nosocomial Infection 7 1 4

Perioperative Cardiac Event 4 3 1

Perioperative Respiratory Event 2 1

Post-operative Renal Impairment 2 1 4

Return to OT 9 1 6 2 2

Transfusion Intra Op 4 7 6 1

Transfusion Post Op 6 4 1

Transfusion Pre Op 2

Treatment Refusal

Undiagnosed Cancer 1

Ureteric Injury

Vascular Injury

Wound Dehiscence 2 1 1

Superficial Diathermy Burn 1 1

Inadvertent Diathermy Bowel

12

Adverse Events 2014

Prof

Carter A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Acute kidney injury (Grade 1)

2

Acute kidney injury (Grade 2) 2

Acute kidney injury (Grade 3) 1 Anaemia (Grade 2) 1 1

Anaemia (Grade 3)

3

Ankle fracture (Grade 1) 1 Atrial flutter (Grade 2) 1

Cervicitis infection (Grade 3)

1 Constipation (Grade 2) 1 Creatinine increased (Grade 2) 1 Fever (Grade 1) 1 Hematoma (Grade 1) 2

Hypocalcaemia (Grade 1) 1 Hypokalaemia (Grade 2) 1 Hypokalaemia (Grade 3)

1

Hypomagnesaemia (Grade 1) 1 1 1

Hypotension (Grade 2) 1 Hypotension (Grade 3)

1

Ileus (Grade 2)

1

Ileus (Grade 3)

1

Infusion related reaction (Grade 2)

Intra-abdominal haemorrhage (Grade 3)

1

Intraop gastrointestinal injury (Grade 1) 1 1 1

Intraop gastrointestinal injury (Grade 2) 1

Intraoperative haemorrhage (Grade 1) 1 Intraoperative haemorrhage (Grade 2)

1

Intraoperative urinary injury (Grade 1) 1 1 Ischemia cerebrovascular (Grade 1) 1 Lung infection (Grade 3) 1

Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify (Grade 3)

1

Pelvic infection (Grade 2) 1

Pelvic infection (Grade 3) 1

Peripheral motor neuropathy (Grade 2) 1

Pleural effusion (Grade 2) 1

Postoperative haemorrhage (Grade 1) 1

Postoperative haemorrhage (Grade 2) 1 1

Postoperative haemorrhage (Grade 3) 1

Respiratory, thoracic and mediastinal disorders - Other, specify (Grade 2) 1

Small intestinal obstruction (Grade 3) 1

Small intestinal obstruction (Grade 4) 1

Surgical and medical procedures - Other, specify (Grade 3) 1

13

Urinary retention (Grade 2) 1 1 1

Urinary tract infection (Grade 2) 1

Urinary tract infection (Grade 3) 1

Urine output decreased (Grade 3) 1

Uterine haemorrhage (Grade 2) 1

Uterine perforation (Grade 2) 1

Vaginal infection (Grade 2) 1

Wound infection (Grade 1) 1

Wound infection (Grade 2) 2 1 2

Wound infection (Grade 3) 1 1

Meeting Attendance

Prof

Carter A/Prof Pather

A/Prof Saidi

A/Prof Tejada-Berges

Attendance Tumour Board 37 34 41 41

Attendance Area M&M 8 6 10 11

14

Publications 1. Ahmadi N, Tan KK, Solomon MJ, Al-Mozany N, Carter J. Pelvic

exenteration for primary and recurrent gynecologic malignancies is safe and achieves acceptable long-term outcomes. J Gynecol Surg 2014;30(5):255-259

2. Carter J, Philp S, O’Connell R. A 5-Year review of gynaecological oncology patients managed by a fast track surgery program. IJCM 2014; 5: 36-41

3. Marriquon-Harris, Rhou J, Storey D, Pather S Prolonged survival after laparoscopic splenectomy for recurrent ovarian cancer and no adjuvant therapy: a report and review of the literature. South Afr J Gynaecol Oncol 2013;5(2):58-61

4. Philp S, Carter J, Pather S, Barnett C, D’Abrew N, White K (2014) Patients’ satisfaction with Fast Track Surgery in Gynaecological Oncology. European Journal of Cancer Care, DOI 10.1111/ecc.12254

5. Richards A, Dalrymple C (2014). Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: An observational study of clinical outcomes for women in low estrogen states. J Obstet Gynaecol Res. 2014 Nov 5. doi: 10.1111/jog.12545.

6. Pather S, Strockyj S, Richards A, Campbell N, De Vries B, Ogle R. Maternal outcome after conservative management of placenta percreta at caesarean section: A report of three cases and a review of the literature. Australian and New Zealand Journal of Obstetrics and Gynaecology 2014; 54(1): 84-87.

7. Pather S, Strockyj S, Richards A, Campbell N, De Vries B, Ogle R (2014). Re: ANZJOG-2013-0458 - Placenta percreta: Multidisciplinary team may not be enough. Australian and New Zealand Journal of Obstetrics and Gynaecology, 54(3), 292-292

8. Robison K, Clark L, Eng W, Wu L, Raker C, Clark M, Tejada-Berges T, Dizon DS. Cervical cancer prevention: Asian-American women's knowledge and participation in screening practices. Women’s Health Issues. 2014 Mar-Apr;24(2):e231-6.

9. Smith SK, Petrak LM, Dhillon HM, Taylor J, Milross CG. Are radiation oncologists aware of health literacy among people with cancer treated with radiotherapy? Eur J Cancer Care (Engl). 2014 Jan;23(1):111-20. doi: 10.1111/ecc.12111. Epub 2013 Aug 19.

10. Sundaresan P, Milross CG, Smith A, Evans A, Stockler MR, King MT. Factors influencing the use of RT in NSW: a qualitative study exploring consumer and health professional perspectives. J Med Imaging Radiat Oncol. 2014 Oct;58(5):625-32. doi: 10.1111/1754-9485.12198. Epub 2014 Jun 19.

11. Wan KM, Rhou YJJ, Berges, T, Campbell N, Carter J, Anderson L, Pather S. Pelvic actinomycosis mimicking ovarian cancer: a report of 3 cases and review of the literature. Austin J Obstet & Gynecol 2014;1(3):1-3

15

12. Thiruthaneeswaran N, Turner S, Milross C, Gogna K. Promoting a research culture among junior radiation oncologists: outcomes from the introduction of the Australian and New Zealand research requirement in training. Clin Oncol (R Coll Radiol). 2014 Mar;26(3):162-73.

International Presentations 1. Anderson L. Smooth muscle tumours of uterus, oral presentation,

Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.

2. Anderson L. Adenosarcoma with sarcomatous overgrowth, oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.

3. Anderson L. Primary peritoneal carcinoma, oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.

4. Anderson L. Molecular update on serous adenocarcinomas, for oral presentation, Annual General Meeting, New Zealand Society of Pathology, Hamilton New Zealand, October 2014.

5. Anderson L. Adenosarcoma with sarcomatous overgrowth, oral presentation, XXXth Congress of the International IAP, Bangkok Thailand, October 2014.

6. Anderson L, Selinger YB, Carter J, O’Toole S, Beale P. Oncongene mutation testing in low grade serous adenocarcinomas of ovary and borderline ovarian tumours in an Australian tertiary care referral setting. Poster presentation. Int Gyn Cancer Society. Melbourne Australia. 8th -11th November 2014.

7. Davis G, Anderson l, Pather S. Oral poster presentation Extramammary Pagets disease of the cervix mimicking carcinoma on cytology. RCOG World Congress 2015. Joint RCOG/RANZCOG Event. Brisbane Convention and Exhibition Centre, Australia 12-15 April 2015.

8. Morton R, Pather S. Oral Poster Presentation (Accepted Dec 2014)The Great Mimicker: Peritoneal Tuberculosis RCOG World Congress 2015: Joint RCOG / RANZCOG Event, Brisbane Convention and Exhibition Centre, Australia, on 12-15 April 2015.

9. Tejada-Berges T. Cervical Cancer Screening as an Effective Model of a Screening test. Advanced Course in Medical Education, Hoc Mai Foundation/University of Sydney, Hanoi, Vietnam, 10th September, 2014.

10. Tejada-Berges T. Writing an Academic CV: Putting Your Best Foot Forward. Advanced Course in Medical Education, Hoc Mai Foundation/University of Sydney, Hanoi, Vietnam, 11th September 2014.

National Presentations 1. Anderson L, Yu B, Sellinger C, Carter J, O’Toole S and Beale P.

Oncogene mutation testing in low grade serous adenocarcinomas of ovary and borderline ovarian tumours in an Australian tertiary care

16

referral setting. Poster presentation at the 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.

2. Anderson L. Gynaecological cytology, Oral presentation, Glandular lesions on ThinPrep cytology, Australian Society of Cytology Annual General Meeting, Darwin, October 2014.

3. Anderson L. Hereditary gynaecological malignancies, Guest lecture, Oral presentation, Gynaecological Pathology Companion Club, 39th International Scientific Meeting of the Australasian Division of the International Academy of Pathology, 2014.

4. Anderson L. Molecular update on serous adenocarcinomas, Oral presentation, Combined RPAH MD Anderson Course, Sydney, February 7-9th, 2014.

5. Blain G, Pather S, Richards A, Carter J, Saidi S. Outcomes for women presenting with high grade pap smears: Implications for “see and treat”. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014

6. Farrell R, Carter J, Dixon S, Webb P. Lymphadenectomy in early stage high-risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014

7. Mizrahi D, Naumann P, Broderick C, Beale P, Harrison M, Ryan M and Friedlander M. An exercise intervention during chemotherapy for women with recurrent ovarian cancer. ANZGOG ASGO Combined Annual Scientific Meeting 2014 (Abst 22)

8. Nagrial A, Long A, Chin V, Carter J, Beale P. Duration of systemic therapy for ovarian cancer: a systematic review and meta-analysis. Oral presentation Combined ANZGOG/ASGO ASM. Canberra 26-29 March 2014

9. Nagrial A, Chin V, Long A, Carter J, Beale P. Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis. Oral presentation ASCO. 30th May-3rd June 2014, Chicago, Illinois.

USA. Abstract5549. J Clin Oncol 32:5s, 2014 (suppl; abstr 5549) 10. Pather S. Colposcopy. Oral presentation. Management of Cervical

Glandular abnormalities. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May

11. Pather S. Colposcopy. Oral presentation. Management benign vulval conditions. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May

12. Pather S. Colposcopy. Oral presentation. Early invasive cervical cancer. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May

13. Pather S. Colposcopy. Panel discussion. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May

14. Pather S. Colposcopy. Oral presentation. Early invasive cervical cancer. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May

15. Pather S. Colposcopy. Oral presentation. Management of complications of dysplasia treatment. Australian Society of Colposcopy

17

and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2

16. Richards A, Herbst U, Pather S, Saidi S, Tejada-Berges T, Williams P, Tan K, Carter J. HE4, CA125, the Risk of Malignancy Algorithm (ROMA) and the Risk of Malignancy Index (RMI)and complex pelvic masses - a prospective comparison in the pre-operative evaluation of adnexal and pelvic masses in an Australian population. Accepted for E-poster presentation at RCOG World Congress 2015: Joint RCOG/RANZCOG Event, Brisbane, QLD, 12-15 April 2015

17. Tejada-Berges T. Can I still have children, doctor? Fertility-sparing Options for Women Diagnosed with Gynaecologic Cancers. Oral presentation at 10th Annual Educational Symposium of the Lifehouse Gynaecologic Oncology Group. 4th April 2014.

18. Tejada-Berges T. Gynaecological Cancer in Pregnancy. Oral Presentation, ACI Gynaecological Oncology Nurses Group, RPAH, Camperdown, 16th May 2014.

19. Tejada-Berges T. Ovarian Cancer Risk-Reduction Treatment Options. Oral Presentation, 14th Annual BRCA Information Day, Association of Genetic Support of Australasia, Sydney, 12th October 2014.

Local Presentations 1. Anderson L. Placental pathology, Oral presentation, University of

Western Sydney Pathology Course for national pathology registrars, 2014.

2. Anderson L. Biology of cancer lecture, Oral presentation to University of Sydney Nursing Students, Royal Prince Alfred Hospital, 6th May, 2014.

3. Anderson L. Placental pathology, Oral presentation to high risk obstetric morbidity and mortality meeting, Royal Prince Alfred Hospital, 24th May, 2013.

4. Carter J. An overview of apparent early stage cancer of uterine corpus. Presentation Medical Oncology Journal Club. Lifehouse. 10th June 2014

5. Philp S. Nurses Leading the Way: Nurse Led Care at Lifehouse, Lifehouse Gynaecologic Oncology Group, 10th Annual Educational Symposium: A New Beginning, A New Way of Care, Lifehouse, April, 2014.

6. Saidi, S. Trends in Surgery – is More Always Better? Oral presentation, Lifehouse Annual Symposium, 4th March 2014.

Abstracts 1. Adhikari C and Anderson L. Muir-Torre syndrome: a case report,

Poster presentation, Updates, Melbourne, 2014, Abstract in Pathology, Feburary 2014, volume 46, doi10.1097/01.PAT.0000443528.94613.56.

2. McLaren E, White K, Eakin E, Philp S. A Nurse-Led Intervention for Women Following a Diagnosis of Type 1 Endometrial Cancer, Flinders

18

Centre for Innovation in Cancer Survivorship Conference, Adelaide, SA, 6-7th February, 2015 (submitted)

3. Nagrial A, Chin V, Long A, Carter J, Beale P. Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis. Oral presentation ASCO. 30th May-3rd June 2014, Chicago, Illinois.

USA. Abstract5549. J Clin Oncol 32:5s, 2014 (suppl; abstr 5549)

Invited Lectureship, Guest or Program Chair 1. Anderson L. Invited Gynaecological Pathology Workshop over 7-8

May, Royal Hobart Hospital, Hobart Tasmania, May 2014. 2. Anderson L. Invited National Representative for National Coalition of

Public Pathology (NCOPP) for “Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014

3. Carter J. Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. Optimising Recovery After Surgery. Hong Kong. 9th March 2014

4. Carter J. Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 9th March 2014

5. Carter J. Invited Speaker. University of Hong Kong. Department of Obstetrics and Gynaecology. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 12th March 2014

6. Carter J. Program Chair. 10th Annual Advances in Gynaecological Oncology. 4th April 2014

7. Carter J. An overview of apparent early stage cancer of uterine corpus. Presentation Medical Oncology Journal Club. Lifehouse. 10th June 2014

8. Pather S. Session 2 Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014

9. Pather S. Session 1: Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014

10. Harrison M. Co-chair – Guest speakers and Oral Abstracts ANZGOG ASGO Combined Annual Scientific Meeting 2014

11. Harrison M. RCC: Clinical Trials to Real World Patient Outcomes. Clinical case presentation. May 2014, Sydney, Australia

12. Harrison M. ANZGOG consumer engagement session. Practicalities of trials from a researchers perspective as it impacts trial participants. Sept 2014, Sydney Australia

13. Richards A. Screening in Gynaecological Cancers. Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014

14. Richards A. Dysplasia and the Management of Abnormal Pap Smear, Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014

19

Grants and Awards (+/-Submitted) 1. Anderson L (CI), Gupta R (CI), O’Toole S (CI), Carter J (AI) Clark J

(AI), Sydney Local Health District Cancer Services Research Grant for the study of Next Generation Sequencing of HPV driven cervical carcinomas. The study is a collaborative venture with Head and Neck HPV driven carcinomas. $60,000.

2. Hoffmann P, Oehler M, Kock I, Ruszkiewicz A (CI), Carter J (AI). Defining a molecular signature of metastasis in gynaecological cancer. Project Grant 2015. Application ID:1086933. Defining a molecular signature of metastasis in gynaecological cancer. NHMRC 2014

3. Hoffmann, Oehler, Koch, Ruszkiewicz (CI), Carter J (AI). Project Grant 2015. Application ID:1086933. Defining a molecular signature of metastasis in gynaecological cancer. NHMRC 2014

4. Carter J. Article “A 5-Year review of gynaecological oncology patients managed by a fast track surgery program” chosen and promoted on Scientific Research Publishing newsletter. http://image.ljemail.org/archive/nl20140117en.htm?utm_campaign=nl20140117en

Research Supervision 1. Carter J. Thesis Review. Strategies for improving cervical cancer

screening in Laos. Dr Sivixay Thammalangsy. 2014. Prematurely ceased.

2. Carter J. Thesis Review. Lymphadenectomy in early stage high risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Dissertation Masters of Surgery. Dr Rhonda Farrell. 23rd March 2014

3. Carter J. PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014

4. Carter J. CGO Thesis supervision Dr Archana Rao. Venous Thromboembolism Prophylaxis and Surgery for Gynaecological Malignancy – a survey of clinical practice of Certified Gynaecological Oncologists in Australia and New Zealand. 7th July 2014

5. Pather S. Research supervision of Dr Davis on cytological prediction of Pagets disease of the cervix.

6. Pather S. Research supervision of Dr Morton on peritoneal tuberculosis mimicking gynaecologic cancer

7. Pather S . Research supervision of Dr Wan on pelvic actinomycosis. 8. Pather S. Research supervision of Dr Naidu from the University of

Pretoria in South Africa on Quality of life in vulval cancer. 9. Pather S. Clinical Observership Supervisor for Dr Ronald Latap as

part of the International Gynaecological Cancer Society October 2014 10. Philp S. Associate Supervisor for Doctor of Philosophy Candidate:

Testing the feasibility of a brief nurse-led lifestyle intervention for women with type 1 endometrial cancer, School of Nursing, The University of Sydney

20

11. Philp S. Primary Supervisor. Sydney Nursing School, Summer Scholar: The Gynaeoncology Nurse Practitioner Role, Literature review.

12. Philp S. Academic adviser for Master of Cancer and Haematology Nursing Research Thesis Student, Management of postembolisation syndrome in patients who have undergone hepatic transarterial chemoembolisation (TACE) for liver primary neoplasms or liver metastases

13. Saidi S. Supervision of Dr Rhett Morton. Utility of frozen section in the management of adnexal masses

14. Saidi S. Supervision of Dr Gemma Blain. Outcomes for women presenting with high grade pap smears - implications for “see and treat”.

Ethics Approved Studies 1. Rasko J, Marshall A, Bailey C, Anderson L, Pather S, Richards A.

Role of CTCF mutations in endometrial cancer. 2. Anderson L, Oehler M, Carter J, and Hoffmann P, Proteomic

characterization of Endometrial Carcinoma using MALDI technique. 3. Pather S. Protocol C13-0268. The conservative management of young

women up to the age of 2 with cervical intraepithelial neoplasia 2. The prediction of regression (Princess Study). Accepted 07 August 2014

4. Richards. A and Anderson L, HE4 and Pax-8 in endometrial tumours and malignant ascites.

5. Anderson L, O’Toole S, Beale P, Carter J. Oncogene testing of serous borderline tumours and low grade serous adenocarcinomas of ovary.

6. Harrison M. Uptake of invitation to enrol on CART-WHEEL.ORG from Lifehouse and impact on recruitment to CART-WHEEL.ORG for patients with rare gynaecological cancers

7. Morton R, Saidi S. Utility of frozen section in the management of adnexal masses

8. Richards A, Pather S, Williams P, Carter J. HE4, CA125 and pelvic mass - a prospective comparison of the Risk of Malignancy Algorithm (ROMA) and the Risk of Malignancy Index (RMI) in the pre-operative evaluation of adnexal and pelvic masses. (Protocol X12-0266).

9. Richards A, Pather S, Williams P, Carter J. HE4 in gynaecological malignancies. (Protocol amendment for X12-0266).

10. Richards A, Pather S, Williams P, Carter J. Effect of HE4 monitoring and response to chemotherapeutic treatment for patients with primary Epithelial Ovarian Carcinoma (Protocol amendment for X12-0266).

11. Richards A, Pather S, William P, Carter J. Effect of HE4 monitoring and response to chemotherapeutic treatment for patients with recurrent Epithelial Ovarian Carcinoma (Protocol amendment for X12-0266).

12. Richards A, Anderson L, Carter J. The role of HE4 and PAX8 immunohistochemistry in endometrial curettage and hysterectomy specimens (Protocol X13- 0233).

21

13. Richards A, Anderson L, Carter J. The role of HE4 and PAX8 in malignant ascites and disseminated intraperitoneal malignancy (Protocol X13-0234).

14. Tejada-Berges T. Women’s Health after Surgical Menopause Study (protocol submitted for ethics approval).

15. Tejada-Berges T. Anal cytological, histological and HPV distributions in women with a history of high grade cervical/vulval/vaginal disease (protocol submitted for ethics approval).

16. Tejada-Berges T, Duncan R, Richards T, Carter J, Philp S. Study Evaluating the potential to eliminate redundant tests after a diagnosis of molar pregnancy to reflect a changing clinical picture (protocol submitted for ethics approval).

Grant, Trial, Thesis & Manuscript Reviews 1. Anderson L. Examination of an MPhil thesis for University of Sydney

in April 2014, on the characterization of circulating and endometrial dendritic cell populations in fertile and infertile women with and without endometriosis.

2. Anderson L. Manuscript number PAT-D-14-00290, Pathology 13th November, 2014

3. Anderson L. Manuscript number PAT-D-14-00195, Pathology, 2nd August, 2014.

4. Anderson L. Manuscript IMP3 signatures, Journal of Haematology and Oncology, June, 2014.

5. Carter J. Thesis Review. Strategies for improving cervical cancer screening in Laos. Dr Sivixay Thammalangsy. 2014. Prematurely ceased.

6. Carter J. Thesis Review. Lymphadenectomy in early stage high risk endometrial cancer: clinical characteristics and outcomes in an Australian cohort. Dissertation Masters of Surgery. Dr Rhonda Farrell. 23rd March 2014

7. Carter J. PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014

8. Carter J. CGO Thesis supervision Dr Archana Rao. Venous Thromboembolism Prophylaxis and Surgery for Gynaecological Malignancy – a survey of clinical practice of Certified Gynaecological Oncologists in Australia and New Zealand. 7th July 2014

9. Carter J. Manuscript Review. IJG-D-14-00044. 13th January 2014 10. Carter J. Manuscript Review. MJA14.00021. 15th January 2014 11. Carter J. Manuscript Review. AOGS-14-0010. 3rd February 2014 12. Carter J. Manuscript Review. UOG-2014-0038. 8th February 2014 13. Carter J. Manuscript Review. ANS-2014-00145. 13th February 2014 14. Carter J. Manuscript Review. ANZJOG-2014-0024. 13th February

2014. 15. Carter J. Manuscript Review. CJOG-2012-0793. 15th February 2014 16. Carter J. Manuscript Review. AOGS-14-0139. Acta Obstetricia et

Gynecologica Scandinavica 4th March 2014. 17. Carter J. Clinical Trial Review. Protocol X14-0129. 19th April 2014

22

18. Carter J. Manuscript ID ANZJOG-2014-0134. 8th May 2014 19. Carter J. Manuscript ID CJOG-2014-0331.12th May 2014 20. Carter J. Manuscript ID CJOG-2014-0285. 1st June 2014. 21. Carter J. Manuscript APJCO-2014-0131. 4th June 2014 22. Carter J. Manuscript CJOG-2014-0491. 27th June 2014. 23. Carter J. Manuscript CJOG-2014-0490. Journal of Obstetrics and

Gynaecology. 7th July 2014 24. Carter J. Manuscript ANZJOG-2014-0154. 6th August 2014 25. Carter J. Manuscript IJG-D-14-01252. 13th November 2014 26. Carter J. Manuscript W14-1087. American Journal of Obstetrics and

Gynecology. 28th December 2014 27. Pather S. ANZJOG-2013-0415. 4 Jan 2014 28. Pather S. ANZJOG-2014-0091. Australian and New Zealand Journal of

Obstetrics and Gynaecology. 23rd Feb 2014 29. Pather S. ANZJOG-2014-0217. 04 April 2014 30. Pather S. Obstetric Case Reports. Dec 2014. 31. Pather S. Borderline Epithelial tumour of the ovary. A review of 55

patient, Journal of Obstetrics and Gynaecology. July 2014 32. Pather S. Grant Review . Femme: A Phase II Randomised Clinical

Trial of Mirena® ± Metformin Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium. NZ Gynaecologic Research Fund. $5000 26th May 2014

33. Pather S. Grant Review. Femme: Culturing primary ascitic ovarian cancer cells on 3D collagen gels to evaluate drug responsiveness in chemo-naïve and resistant patients. NZ Gynaecologic Research Fund. $5000 26th May 2014

34. Pather S. Grant Review . Femme: A prospective audit of sentinel node biopsy for patients with vulval cancer in Australia and New Zealand. NZ Gynaecologic Research Fund. $5000 26th May 2014

35. Philp S. Abstract Review. International Society of Nurses in Cancer Care (ISNCC), 18th Annual International Conference on Cancer Nursing, Panama City: Panama, 7-11 September, 2014.

36. Philp S. Abstract review. International Gynecologic Cancer Society (IGCS) Nursing and Supportive Care Forum, Melbourne, Vic, 7th November 2014

37. Philp S. Abstract review. Australian College of Nurse Practitioners (ACNP) Conference, Sydney, NSW, September 2014

38. Philp S. Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0694

39. Philp S. Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0796

40. Philp S. Journal of Clinical Nursing, manuscript review, Manuscript ID JCN-2014-0071

41. Philp S. Master of Cancer and Haematology Nursing Research Thesis,

Management of postembolisation syndrome in patients who have

undergone hepatic transarterial chemoembolisation (TACE) for liver

primary neoplasms or liver metastases.

23

42. Saidi S. Manuscript Number ANZJS - ANS-2014-00971. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1st November 2014.

Appointments 1. Carter J. Scientific Advisory Panel The Australian Gynaecological

Cancer Foundation. 24th February 2014. 2. Carter J. Scientific Advisor Panel. Compass Trial. A randomized

controlled trial of primary HPV DNA testing for cervical screening in Australia. March 2014

3. Carter J. Health Care Complaints Commission’s expert advisers panel. 19th March 2014

4. Carter J. Editorial Board Member Austin Journal of Obstetrics and Gynecology. 1st February 2014

5. Pather S. Editorial Board Member Austin Journal of Obstetrics and Gynecology. 1st April 2014

6. Pather S. Member of the Human Research Ethics Committee at Sydney Area Health Service. May 2014

7. Richards A. Membership of Psycho Oncology Co-operative Research Group

8. Tejada-Berges T. September 2014: Clinical Associate Professor, University of Sydney Medical School, Central Clinical School, Discipline of Obstetrics, Gynaecology & Neonatology.

Administrative Responsibilities 1. Anderson L. Head of Cytology, Royal Prince Alfred Hospital. 2. Carter J. Department Head Gynaecological Oncology. Lifehouse 3. Carter J. Committee Member. MDAC. Lifehouse 4. Carter J. Committee Member. Clinical Leadership Committee.

Lifehouse 5. Carter J. Committee Member. RPAH Theatre Procedures Committee. 6. Carter J. Committee Member. Standards Setting: Patient Identification.

Lifehouse

7. Carter J. Scientific Advisory Panel The Australian Gynaecological Cancer Foundation. 24th February 2014.

Course Organisation 1. Carter J, Philp S, Tejada-Berges T, Young C. Course Convenor. 10th

Annual Advances in Gynaecological Oncology Symposium: A New Beginning, A New Way of Care. 4th April 2014

2. Pather S. Organiser ASCCP Course. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014

3. Pather S. ASCCP Treatment Course. Australian Society of Colposcopy and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2014

24

4. Philp S. Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney

5. Philp S. Organising Committee. ACI GONG, “Gynaecological Cancers 10 years on”, RPAH, 16th May 2014

6. Philp S. Clinical Stream Coordinator, Cancer and Aged Care, The 9th Conference of The Australian College of Nurse Practitioners, ‘New Frontiers: Building future generations, Sydney, September 2014

7. Richards A. Assistant for ASCCP Colposcopic Treatment Course, RPAH, 25th October 2014.

8. Tejada-Berges T. Assistant for ASCCP Colposcopic Treatment Course, RPAH, 25th October 2014.

Committee Membership 1. Anderson L. Royal College of Pathologists of Australasia, RCPAQAP

Gynaecological Pathology Quality Program, 2014. 2. Anderson L. Invited National Representative for National Coalition of

Public Pathology (NCOPP) for “Consultation session on the renewal of the National Cervical Screening Program. Department Health, Australian Government Canberra. 25th November 2014

3. Anderson L. Organizing Committee, 9th Asia Pacific International Academy of Pathology Congress, Brisbane 2015.

4. Harrison M. Australian and New Zealand Gynaecological Oncology Group. Quality assurance committee

5. Harrison M. Australian and New Zealand Gynaecological Oncology Group. Ovarian cancer working group

6. Richards A. Research Advisory Committee for RANZCOG. 7. Richards A. Ovarian Tumour-type work Research advisory group,

ANZGOG. 8. Philp S. NSW ACI Gynaecological Oncology Nurses Group (GONG)

Executive Committee 9. Philp S. ICGS Nursing and Supportive Care Forum Organising

Committee 10. Philp S. Australian College of Nurse Practitioners (ACNP) 2014

Conference Organising Committee Cancer Stream 11. Philp S. Lifehouse, Inpatient Forms Committee 12. Philp S. Lifehouse, Falls Prevention Standard, Working Party 13. Philp S. Lifehouse/SLHD Lymphoedema Focus Group 14. Philp S. Sydney Nursing School, Local Disability Action Plan, Working

Party 15. Saidi S. ANZGOG Cervical Tumour Type Working Group. 16. Saidi S. Governance Working Group of ASGO. 17. Saidi S. British Gynaecological Cancer Society surveys peer review

committee.

Selection Committees 1. Anderson L. Cytology Scientist In-charge Interview. July 2014. 2. Anderson L. Staff Specialist Interview. November 2014.

25

3. Carter J. Clinical Trials Nurse. 16th-17th January 2014 4. Carter J. Clinical Trials Nurse. 19th June 2014

Media & Fund Raising 1. Carter J. Interview Modern Medicine. Long term outcomes for women

treated for cervical precancer. 22nd Jan 2014 2. Carter J. Invited speaker. Trailblazer Appreciation Function. 16th

December 2014

College Activities; Lectures 1. Brand A, Do V, Harnett P and Anderson L, Gynaecological Pathology

Tumour Board Oral Presentation, October 2014, Rydges Hotel for MRANZCOG registrars.

2. Pather S. Examiner for the CGO subspeciality in Gynaecologic Oncology. July 2014

3. Richards A. Screening in Gynaecological Cancers. Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014

4. Richards A. Dysplasia and the Management of Abnormal Pap Smear, Diploma examination revision course, RANZCOG, Rydges Hotel, North Sydney 25 November 2014

5. Richards A. Review of 4 FRANZCOG trainee research proposals. RANZCOG Research Advisory Committee

6. Tejada-Berges T. MRANZCOG Revision Course: Surgical Pelvic Anatomy, Rydges Hotel, North Sydney, 27th October 2014.

University Activities 1. Carter J. Registration as Auxillary Supervisor (Associate Supervisor) of

Higher Degree Research Candidates at Sydney Medical School. 26th February 2014.

2. Carter J. External examiner for University of Hong Kong MBBS Examination. 10th-14th March 2014

3. Carter J. Associate PhD Supervision. Dr Rachael Rodgers. The ex vivo stimulation of ovaries to facilitate oocyte collection prior to gonadotoxic treatment. The University of Sydney. 2014

4. Carter J. SCORPIO: HPV and Vaccination. 20th October 2014 5. Pather S. Cervix Cancer SCORPIO. Organiser 20th October 2014. 6. Pather S. Management of the abnormal pap smear. Medical Student

Lecture KPEC RPA Hospital 18/03/14 7. Pather S. Management of Postmenopausal Bleeding. Medical Student

Lecture KPEC RPA Hospital 18/03/14 8. Pather S. Management of the abnormal pap smear. Medical Student

Lecture KPEC RPA Hospital 20/05/14 9. Pather S. Management of Postmenopausal Bleeding. Medical Student

Lecture KPEC RPA Hospital 20/05/14

26

10. Pather S. Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 22/07/14

11. Pather S. Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 22/07/14

12. Pather S. Management of the abnormal pap smear. Medical Student Lecture KPEC RPA Hospital 07/10/14

13. Pather S. Management of Postmenopausal Bleeding. Medical Student Lecture KPEC RPA Hospital 07/10/14

14. Philp S. Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney

15. Philp S. Meeting with ANMAC regarding Nurse Practitioner Education and reaccreditation of Master of Nursing (Nurse Practitioner), Sydney Nursing School.

16. Richards A. SCORPIO: Histopathology of dysplasia and cervical cancer. 20th October 2014

17. Tejada-Berges T. Lecture: Evaluation of the Adnexal Mass. 21st March 2014.

18. Tejada-Berges T. Lecture: Evaluation of the Adnexal Mass. 23rd May 2014.

19. Tejada-Berges T. Lecture: Evaluation of the Adnexal Mass. 24th July 2014.

20. Tejada-Berges T. Lecture: Evaluation of the Adnexal Mass. 10th October 2014.

21. Tejada-Berges T. Cervix Cancer Scorpio Lecture: Clinical Staging of Cervix Cancer. 20th October 2014.

22. Tejada-Berges T. Cervix Cancer Scorpio Lecture: Management of Cervix cancer. 20th October 2014.

23. Tejada-Berges T. Lecture on Hereditary Breast and Ovarian Cancer Syndrome, University of Sydney Medical School, Postgraduate Course in Reproductive Health Sciences and Human Genetics. 12th August, 2014.

24. Tejada-Berges T. Tutor for Problem-Based Learning, Block 1 Foundation Block, University of Sydney Medical School, March 13, 20 and 27, April 3 and 10, 2014.

25. Saidi S. Cervical Cancer Screening and Management of the Abnormal Pap Smear. Presentation University of Sydney Medical School. 27th October 2014

26. Saidi S. SCORPIO session training. University of Sydney Medical School 27th October 2014.

27. Saidi S. Tutor in clinical oncology. University of Sydney Medical Students 21st October – 4th November 2014.

28. Saidi S. Medical Student PPD interviews. University of Sydney Medical School. 16th – 17th July 2014.

27

Courses/Conferences Attended 1. Anderson L. MD Anderson RPAH Pathology Course, March, 2014. 2. Anderson L. Australasian Division of the International Academy of

Pathology Meeting, Brisbane, June, 2014. 3. Anderson L. Australian Society of Cytology Annual General Meeting,

Darwin, October 2014. 4. Anderson L. XXXth Congress of the International IAP, Bangkok

Thailand, October 2014. 5. Anderson L. Annual General Meeting, New Zealand Society of

Pathology, Hamilton New Zealand, October 2014. 6. Anderson L. 15th Biennial Meeting of the International Gynecologic

Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.

7. Carter J. Attended and Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. Optimising Recovery After Surgery. Hong Kong. 9th March 2014

8. Carter J. Attended and Invited Speaker. Postgraduate Seminar Hong Kong College of Obstetricians & Gynaecologists. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 9th March 2014

9. Carter J. Attended and Invited Speaker. University of Hong Kong. Department of Obstetrics and Gynaecology. An Overview of Apparent Early Endometrial Cancer. Hong Kong. 12th March 2014

10. Carter J. Attended. ANZGOG/ASGO Combined Annual Scientific Meeting. Hyatt Hotel Canberra. 26-29th March 2014. Approved 26 CPD Points

11. Harrison M. ANZGOG/ASGO Combined Annual Scientific Meeting. Canberra, Australia 26th – 30th March 2014

12. Harrison M. 15th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2014) November 8-11, Melbourne, Australia, 2014.

13. Pather S. Australian Society of Colposcopy and Cervical Pathology treatment course. Park Royal Darling Harbour, 4th May 2014

14. Pather S. Australian Society of Colposcopy and Cervical Pathology treatment course. RPA Hospital, Camperdown, 25th October 2

15. Pather S. Inaugural Peritonectomy Conference St George Hospital Sydney. 4-5 November 2014

16. Philp S. Cancer Nurse Practitioners of Australia, Masterclass, Lifehouse, March 2014

17. Philp S. ACI GONG, “Gynaecological Cancers 10 years on”, RPAH, 16th May 2014

18. Philp S. ICGS and CNSA Nursing and Supportive Care Forum, Melbourne, Vic, 7th November, 2014

19. Philp S. ICGS 15th Biennial Meeting, Melbourne, Vic, 8-11th November, 2014

20. Richards A. Attended. ANZGOG/ASGO Combined Annual Scientific Meeting. Hyatt Hotel Canberra. 26-29th March 2014. Approved 26 CPD Points

21. Saidi S. Joint ANZGOG and Australian Society of Gynaecologic Oncologists Annual Scientific Meeting. Canberra, 26th-29th March 2014.

28

22. Saidi S. 15th Biennial meeting of the IGCS. Melbourne, 8th-11th November 2014.

23. Saidi S. C-Quip certification for the ASCCP. 20th October 2014. 24. Tejada-Berges T. ANZGOG/ASGO Combined Annual Scientific

Meeting. Canberra, Australia 26th – 30th March 2014. 25. Tejada-Berges T. 15th Biennial Meeting of the International

Gynecologic Cancer Society. Melbourne, Australia. 8th-11th November 2014.

29

Trials List Gynaecological Oncology Clinical Trials List Presenter Comment

Ovary

LH14.018: ICON 8. An international phase 3 randomised trial of dose fractionated chemotherapy compared to standard 3 weekly chemotherapy following immediate primary surgery or as part of delayed primary surgery for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

Beale & Harrison

Approached: 3 Recruited: 1 Active: 1 Site activated 29 August 2014 Recruitment suspended 27 November 2014

LH14.029: MEKi012: Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer

Beale & Harrison

Enrolment stopped by sponsor (16 Dec 2014)

LH14.024: OVAR 2.21: A prospective randomized Phase III trial of carboplatin/ gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Beale & Harrison

Site activated 18 Sep 2014 Approached: 3

X14.0215: feMMe study A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium (ANZGOG 1301)

Carter

Awaiting update from Ethics

Identification of protein markers suitable for early detection of ovarian cancer

Beale Dalrymple Carter Pather

Open; RPA: 344 P.B to draft letter to investigator – keen to continue participating ?Transition in Feb2015

HE4/ROMA Index Study

Richards

Open; RPA:46 LH SSA Pending

HE4 and gynaecological malignancies: analysis of the significance of HE4 in suspected ovarian carcinoma and its relationship with endometrial, vulval, vaginal, cervical and GTD.

Richards

Open; LH SSA Pending EN:6, CE:3

HE4 kinetics: effect of HE4 monitoring and response to primary chemotherapeutic treatment for patients with epithelial ovarian carcinoma

Richards

Open; LH SSA Pending

HE4 kinetics: effect of HE4 monitoring and response to chemotherapeutic treatment for patients with recurrent epithelial ovarian carcinoma

Richards

Open; LH SSA Pending

LH13.003: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms

Beale & Harrison

Recruited: 30 Active: 5 Off-treatment: 18

30

Deceased: 7 Potential: 2 (as of 22/12/14)

X14-0396: WHAM: Impact of risk reducing bilateral salpingoophorectomy on non-cancer outcomes in high risk young women: a multicentre prospective trial

Tejada-Berges

Reply received 17/12/14 - Queries to be addressed by TTB and CM

Prediction of high grade cervical dysplasia on histopathology in patients with HSIL on pap smear

Blain & Saidi

For analysis and writing up

INOVATe: Individualised Ovarian cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care

Beale

Grant application submitted – feedback pending April 2015

Corpus

STATEC: A randomized trial of Lymphadenectomy to direct adjuvant therapy in high risk endometrial cancer. An international trial developed by the Gynaecological Cancer Inter Group (GCIG).

Saidi

Has ANZGOG approval – NEAF to be submitted; recommended to submit to RPAH or Concord HREC

Cervix

LH13.056: OUTBACK: ANZGOG 0902: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone.

Beale

Recruited: 3 Active: 2 Follow-up: 0 Deceased: 1 Brachytherapy dosing issue – cannot comply with protocol

Dysplasia

X13-0268: PRINCESS2: The prediction of regression in CIN2

Pather

Contractual issues; discussions still ongoing- still waiting for local district to review MOU

Anal cytological and HPV distribution in women with a history of high grade cervical/vulval/vaginal disease

Tejada-Berges

Still going through ethics

Vulva

Other

HPV self-testing

Herbst

Resubmitted to RPA HREC on 26 November

31

2014

Centre for Analysis of Rare Tumours (CART-WHEEL)

Harrison

LNR submitted to HREC – No response yet

X14-0344 & LNR/14/RPAH/465 – Maintenance of a Gynaecologic Oncology database and patient management system

Gynaecological Oncology

LNR submitted; S.S. to address queries (3 Dec 14)

Clinical audit of single surgeon experience with Fast Track Surgery in gynaecological patients

Carter

LNR submitted to RPA HREC

Carbohydrate Loading in Gynaecologic Oncology Open Surgery

Saidi

Queries to be addressed

Studies in Follow Up Phase

LH13.039: OVAR12. Multicentre randomised double blind Phase 3 trial to investigate the efficacy of and safety of BBIF 1120 in combination with carboplatin and Paclitaxel compared to placebo plus carboplatin and Paclitaxel in patients with advanced ovarian cancer

Beale

Transferred to LH 12/12/13. 2 pts remain in follow-up

LH13.036: OVAR 16: Pazopanib, an oral angiogenesis inhibitor, as maintenance therapy following the completion of first line platinum based chemotherapy in women with advanced ovarian cancer

Beale

Transferred to LH 10/12/2013. 3 Pts remain in follow-up

Development of a Q-Stream Knowledge Translation Program on referral for Ovarian Cancer for Medical and Gynaecological Oncologists

Genetics

Closed – Data analysis

LH13.034: Symptom Benefit: QOL ANZGOG study in Platinum Refractory Ovarian cancer

Beale & Harrison

RECRUITMENT CLOSED 05/01/2015 Recruited: 13 Active: 1 Follow-up: 8 Deceased: 4